Trinity Biotech Plc Stock Price, News & Analysis

Trinity Biotech plc (Nasdaq: TRIB) announced on April 19, 2023, that it has received a notice from Nasdaq regarding non-compliance with Listing Rule 555(a)(2), due to the bid price of its American depositary shares falling below $1.00 for 30 consecutive business days.

The company has until October 16, 2023, to regain compliance by achieving a closing bid price of $1.00 for at least ten consecutive business days. If not compliant, Trinity may qualify for an additional 180-day grace period if it meets other listing requirements. Management will actively monitor the bid price and explore options to regain compliance.

The global transport media market was valued at USD 13.15 billion in 2022 and is projected to decline to USD 12.59 billion by 2028. This decrease is attributed to shifting demands post-COVID-19, despite technological advancements made during the pandemic which enhanced diagnostic capabilities. The market has seen significant product introductions, particularly for viral transport media, which captured a 55.75% share in 2022 due to high diagnostic needs related to COVID-19 and emerging diseases like monkeypox. Regions like North America dominate with a 33.02% market share, influenced by high testing rates and advancements in research. The diagnostic segment is leading applications with 65.75% market share, although future growth may be challenged as demand for COVID-19 diagnostics declines.

The global enteric disease testing market is projected to grow from $3.8 billion in 2022 to $5.3 billion by 2032, achieving a CAGR of 3.3% during the forecast period of 2023-2032. Key growth drivers include increased awareness in developing countries, a surge in enteric disease cases, and advancements in testing technologies. The reagents and consumables segment led the market in 2022 and is expected to maintain its dominance, while the molecular diagnostics segment is anticipated to grow the fastest at a CAGR of 4.1%. Hospital laboratories accounted for the largest market share and are expected to see a CAGR of 3.6%. However, high costs associated with molecular diagnostics could hinder growth. North America dominated the market in 2022, with the Asia-Pacific region expected to witness the highest growth rate of 5.2%.

Trinity Biotech (TRIB) announced the sale of its Fitzgerald Industries life sciences business to Biosynth for approximately $30 million. This move aligns with Trinity's strategy to focus on diabetes care and decentralized diagnostics, as Fitzgerald's operations no longer fit its long-term goals. The sale is projected to reduce Trinity's net debt by about 40% and strengthen its balance sheet. Fitzgerald Industries generated around $12 million in revenue for the year ended December 31, 2022, and was EBITDA positive. Trinity plans to use approximately $11 million of the proceeds to repay senior secured debt and has amended its loan agreement, easing revenue covenants. This transaction is expected to lower debt servicing costs and provide capital for future growth.

The pregnancy test kits market is projected to grow at a CAGR of 5.08% from 2022 to 2028, reaching a market size of USD 2.28 billion by 2028, up from USD 1.70 billion in 2022. The surge in demand for rapid and self-contained kits, driven by rising unplanned pregnancies and the increasing number of working-class women, is contributing to this growth. The report highlights the growing adoption of digital pregnancy test kits and advances in testing technologies, improving sensitivity and efficiency. Major market players are focusing on enhancing user experience through innovative features. The most significant geographical penetration is expected in APAC. The report outlines factors like the rising awareness and accessibility of kits in middle-income regions as pivotal growth drivers.